Cayuga Biotech develops proprietary biomimetic hemostatic drugs that enhance the body’s natural ability to control bleeding, particularly in non-compressible hemorrhage scenarios where traditional methods fail. The company targets the urgent need for effective treatments in both life-threatening hemorrhage and rare bleeding disorders, addressing the limitations of existing therapies that pose safety risks.
Funding
Funding not disclosed
Founders
Product
Problem
Hemorrhage is a leading cause of preventable death, especially in cases of non-compressible bleeding where traditional methods like tourniquets and topical agents are ineffective. Existing systemic therapies for major hemorrhage carry safety risks due to the potential for off-target clotting in healthy tissues. Millions also suffer from inherited bleeding disorders, many lacking approved treatments or facing limitations with current therapies.
Solution
Cayuga Biotech develops biomimetic hemostatic drugs designed to enhance the body’s natural ability to control bleeding, particularly in non-compressible hemorrhage scenarios. Their proprietary science offers a novel approach to tackling hemorrhage, addressing the unmet need for effective and safe treatments. The company's focus is on developing solutions that minimize the risk of off-target clotting while providing effective hemostatic control. This approach aims to improve outcomes in life-threatening hemorrhage and provide new options for individuals with rare bleeding disorders.
Target Audience
The primary target audience includes medical professionals treating patients with severe bleeding due to trauma, surgery, or childbirth, as well as individuals with inherited bleeding disorders.
Features
- Biomimetic approach that enhances the body's natural clotting mechanisms.
- Designed for use in non-compressible hemorrhage, where traditional methods are ineffective.
- Aims to minimize the risk of off-target clotting in healthy tissues.
- Potential application in treating both life-threatening hemorrhage and rare bleeding disorders.